Spots Global Cancer Trial Database for Safety and Efficacy of γδ T Cell Against Gastric Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety and Efficacy of γδ T Cell Against Gastric Cancer
Official Title: γδ T Cell Immunotherapy for Treatment of Gastric Cancer
Study ID: NCT02585908
Conditions
Study Description
Brief Summary: In this study, safety and effects of γδT cells on human gastric cancer are going to be investigated.
Detailed Description: PBMC of the patient will be separated from peripheral blood. After making them potential cancer killer γδ T Cell and CIK, they will be infused to the patients as immunotherapy.
Keywords
Eligibility
Minimum Age: 30 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China
Huai'An First People'S Hospital, Huaian, Jiangsu, China
Hangzhou Cancer Hospital, Hangzhou, Zhejiang, China
Contact Details
Name: li gangyi, master
Affiliation: Beijing Doing Biomedical Co., Ltd.
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
